The Vanguard Group Discloses Position in Avadel Pharmaceuticals

The Vanguard Group, Inc. has filed a Form 8.3 with the Irish Takeover Panel concerning its interests in Avadel Pharmaceuticals plc. The document reveals key information about Vanguard’s holdings and transactions in Avadel’s US$0.01 ordinary shares, as part of the Irish Takeover Rules. As of October 28, 2025, Vanguard owns and controls 5,525,182 ordinary shares, representing 5.67% of Avadel's total securities.

The disclosure lists a recent purchase of 324 ordinary shares at a price of 18.59 USD per unit. Vanguard has reported no cash-settled or stock-settled derivative positions. Furthermore, there are no indemnity or other arrangements related to Avadel's securities. No Supplemental Form 8 has been attached to this disclosure.